FY2025 EPS Estimates for Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Boosted by Brookline Capital Management

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS - Free Report) - Equities research analysts at Brookline Capital Management lifted their FY2025 earnings estimates for Syros Pharmaceuticals in a research note issued on Tuesday, May 14th. Brookline Capital Management analyst L. Cann now expects that the company will earn ($0.77) per share for the year, up from their previous estimate of ($0.91). The consensus estimate for Syros Pharmaceuticals' current full-year earnings is ($3.56) per share.

A number of other brokerages have also recently weighed in on SYRS. HC Wainwright reiterated a "buy" rating and issued a $15.00 target price on shares of Syros Pharmaceuticals in a report on Wednesday. StockNews.com raised Syros Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Wednesday. Finally, Piper Sandler reissued an "overweight" rating and set a $13.00 target price on shares of Syros Pharmaceuticals in a research report on Wednesday, April 3rd.

Syros Pharmaceuticals Trading Down 0.5 %

Shares of SYRS traded down $0.03 during mid-day trading on Friday, reaching $5.45. The company had a trading volume of 163,176 shares, compared to its average volume of 198,420. The stock has a market cap of $145.68 million, a price-to-earnings ratio of -1.08 and a beta of 1.75. The company has a current ratio of 3.01, a quick ratio of 3.95 and a debt-to-equity ratio of 1.97. The firm has a fifty day simple moving average of $5.47 and a 200-day simple moving average of $5.54. Syros Pharmaceuticals has a fifty-two week low of $2.09 and a fifty-two week high of $8.17.

Syros Pharmaceuticals (NASDAQ:SYRS - Get Free Report) last released its earnings results on Tuesday, May 14th. The company reported ($0.79) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.10. Syros Pharmaceuticals had a negative net margin of 1,656.34% and a negative return on equity of 395.36%. During the same period in the previous year, the firm earned ($0.85) EPS.

Institutional Trading of Syros Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. Assenagon Asset Management S.A. boosted its position in shares of Syros Pharmaceuticals by 142.2% in the third quarter. Assenagon Asset Management S.A. now owns 25,130 shares of the company's stock worth $99,000 after buying an additional 14,754 shares during the period. Acadian Asset Management LLC purchased a new position in Syros Pharmaceuticals in the 1st quarter worth approximately $91,000. Avidity Partners Management LP grew its position in Syros Pharmaceuticals by 5.8% in the fourth quarter. Avidity Partners Management LP now owns 1,673,538 shares of the company's stock valued at $13,037,000 after acquiring an additional 92,396 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Syros Pharmaceuticals by 21.3% during the first quarter. Vanguard Group Inc. now owns 928,046 shares of the company's stock valued at $4,965,000 after purchasing an additional 163,234 shares during the period. Finally, Flagship Pioneering Inc. raised its stake in shares of Syros Pharmaceuticals by 30.2% during the fourth quarter. Flagship Pioneering Inc. now owns 1,293,848 shares of the company's stock valued at $10,079,000 after purchasing an additional 300,000 shares during the period. 91.47% of the stock is owned by hedge funds and other institutional investors.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.